RenovoRx (RNXT) Research Hub

RenovoRx (RNXT) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 1.31 USD (+1.55%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.58, market cap 0.03B. This hub links to the full technical, earnings and options research available for RNXT.

Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ

SectorHealthcare (Biotechnology)
ExchangeNASDAQ, US
Last close1.31 USD (+1.55%)
52-week range0.84 USD – 2.54 USD
Trend regimeRange
14-day RSI42.9 (Bearish)
Trailing P/E-2.58
Market cap0.03B
Dividend yield0.00%
Next earnings2026-08-13

Available research for RNXT

Earnings

RNXT earnings date and last-quarter result: next report 2026-08-13, last quarter in line, P/E -2.58. Updated 2026-07-23.

Options: Covered Call

Covered Call on RNXT: how it works, illustrative setup around the real 1.31 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Iron Condor

Iron Condor on RNXT: how it works, illustrative setup around the real 1.31 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Protective Put

Protective Put on RNXT: how it works, illustrative setup around the real 1.31 USD price, max profit/loss, breakeven and when to use it. Educational.

Technical

RNXT technical analysis: range, last 1.31 USD, RSI 42.9, 52w range 0.84 USD–2.54 USD, real support/resistance. Updated 2026-10-26.

More on SniperIQ

Frequently asked questions

What sector is RNXT in?

RenovoRx (RNXT) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.

Is RNXT in an uptrend or downtrend?

As of 2026-10-26, RNXT is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.

What is RNXT's trailing P/E ratio?

RNXT's trailing P/E is -2.58, with a market cap of 0.03B. See the earnings research page for full valuation detail.

When does RNXT next report earnings?

RNXT is next scheduled to report earnings on 2026-08-13.